Q&A

Expert Q&A
Expert Q&A
03/06/2026
Anum Saeed, MD
In this Q&A, Anum Saeed, MD discusses how cardiologists must think beyond LDL and blood pressure, leveraging GLP-1 receptor agonists, SGLT-2 inhibitors, and emerging therapies to reduce cardiovascular...
03/06/2026
Expert Q&A
Expert Q&A
02/10/2026
Mary Elizabeth Patti, MD
From medication access to adherence challenges, social vulnerability can shape diabetes outcomes. In this expert Q&A, Dr. Mary Elizabeth Patti reviews evidence showing that metabolic surgery delivers...
02/10/2026
Expert Q&A
Expert Q&A
02/05/2026
Brian A. Bergmark, MD
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
02/05/2026
Expert Q&A
Expert Q&A
12/22/2025
Brady L. Stein, MD
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
12/22/2025
Expert Q&A
Expert Q&A
11/27/2025
Joel M. Gelfand, MD, MSCE
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
11/27/2025
Sponsored Q&A
Sponsored Q&A
11/24/2025
Douglas DiRuggiero, DMSc, MHS, PA-C
Veteran dermatology Physician Assistant Douglas DiRuggiero, PA-C, DMSc, shares practical insights on how he incorporates ZORYVE® (roflumilast) into the treatment of atopic dermatitis, seborrheic...
11/24/2025
Expert Q&A
Expert Q&A
11/04/2025
Daniel Lenihan, MD, FACC, FESC
Daniel Lenihan, MD, FACC, FESC, FIC-OS, a cardio-oncologist and founder of the International Cardio-Oncology Society, discusses cardiovascular risks associated with Bruton's tyrosine kinase inhibitors in...
11/04/2025
SOHO 2025 Conference Coverage
SOHO 2025 Conference Coverage
09/23/2025
Junaid Anwar, MD, discusses a meta-analysis of five landmark trials evaluating Janus kinase inhibitors for myelofibrosis, highlighting first-line efficacy and tolerability with ruxolitinib, second-line...
09/23/2025
PUPC Conference Coverage
PUPC Conference Coverage
09/19/2025
Shanti Eswaran, MD, and Joel Heidelbaugh, MD, share evidence-based strategies to help primary care clinicians diagnose and manage IBS and chronic constipation with confidence.
09/19/2025
ACP Internal Medicine Meeting 2025 Expert Q&A
ACP Internal Medicine Meeting 2025 Expert Q&A
09/11/2025
Matthew B. Carroll, MD, MACP, FACR
Matthew B. Carroll, MD, MACP, FACR, discusses his ACP Internal Medicine Meeting presentation on four foot and ankle conditions frequently seen in primary care. He shares clinical considerations for initial...
09/11/2025